Eleven Biotherapeutics Inc. (EBIO) Major Shareholder Ventures Fund Iv L.P Flagship Sells 53,917 Shares
Eleven Biotherapeutics Inc. (NASDAQ:EBIO) major shareholder Ventures Fund Iv L.P Flagship sold 53,917 shares of the business’s stock in a transaction on Tuesday, September 20th. The shares were sold at an average price of $3.39, for a total value of $182,778.63. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Ventures Fund Iv L.P Flagship also recently made the following trade(s):
- On Wednesday, September 21st, Ventures Fund Iv L.P Flagship sold 322,723 shares of Eleven Biotherapeutics stock. The shares were sold at an average price of $3.75, for a total value of $1,210,211.25.
- On Monday, September 19th, Ventures Fund Iv L.P Flagship sold 9,700 shares of Eleven Biotherapeutics stock. The shares were sold at an average price of $3.31, for a total value of $32,107.00.
Eleven Biotherapeutics Inc. (NASDAQ:EBIO) traded up 3.86% during mid-day trading on Wednesday, reaching $3.50. The company had a trading volume of 6,214,655 shares. The stock has a 50-day moving average of $4.45 and a 200 day moving average of $2.19. The company’s market capitalization is $53.88 million. Eleven Biotherapeutics Inc. has a 12-month low of $0.25 and a 12-month high of $5.97.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/eleven-biotherapeutics-inc-ebio-major-shareholder-ventures-fund-iv-l-p-flagship-sells-53917-shares.html
Eleven Biotherapeutics (NASDAQ:EBIO) last posted its earnings results on Friday, August 12th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter. Eleven Biotherapeutics had a negative net margin of 2,995.34% and a negative return on equity of 207.40%. On average, analysts expect that Eleven Biotherapeutics Inc. will post ($1.75) EPS for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp raised its position in Eleven Biotherapeutics by 13.2% in the second quarter. Bank of New York Mellon Corp now owns 67,483 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 7,846 shares in the last quarter. Boxer Capital LLC bought a new position in Eleven Biotherapeutics during the second quarter worth $1,670,000. Sabby Management LLC raised its position in Eleven Biotherapeutics by 525.6% in the first quarter. Sabby Management LLC now owns 1,213,984 shares of the biopharmaceutical company’s stock worth $387,000 after buying an additional 1,019,943 shares in the last quarter. Flagship Ventures Fund IV General Partner LLC bought a new position in Eleven Biotherapeutics during the second quarter worth $2,464,000. Finally, Flagship Ventures Fund IV L.P. bought a new position in Eleven Biotherapeutics during the first quarter worth $469,000. Institutional investors own 24.81% of the company’s stock.
Eleven Biotherapeutics Company Profile
Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.
Receive News & Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.